ZymoGenetics, Inc. engages in the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases in the areas of hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections. Its preclinical stage internal products include IL-31, for the treatment of atopic dermatitis and inflammatory diseases. The company’s phase II internal candidates comprise atacicept for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; and IL-21 for the treatment of metastatic melanoma/metastatic renal cell carcinoma. Its phase I out-licensed candidates consist of rFactor XIII for congenital...